This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Helsinn Healthcare SA
Drug Names(s): Ipamorelin
Description: Ipamorelin is a pentapeptide selective growth hormone secretagogue and agonist of the ghrelin receptor. The ghrelin receptor is found both in the central nervous system (hypothalamus and pituitary), and in the gastrointestinal tract and vasculature. In the central nervous system, activation of the receptor can stimulate growth hormone secretion. In the GI tract, they have gastrointestinal prokinetic activity.
Deal Structure: On September 19, 2006, Sapphire Therapeutics announced it had licensed ipamorelin from Novo Nordisk, without disclosing terms.
On January 28, 2009, Helsinn announced they had acquired Sapphire Therapeutics.
Partners: Novo Nordisk A/S
Additional information available to subscribers only: